Tuberous Sclerosis Complex (TSC) — a multisystem autosomal dominant neurodevelopmental disorder caused by loss-of-function mutations in either TSC1 (encoding hamartin, chromosome 9q34) or TSC2 (encoding tuberin, chromosome 16p13.3), with TSC2 mutations accounting for approximately 70% of identified cases and generally correlating with more severe phenotype, arising in approximately 1 in 6,000 live births with an estimated prevalence of 1 in 25,000 in the general population making it one of the most common single-gene disorders causing intellectual disability and epilepsy — operates through constitutive hyperactivation of the mTORC1 (mechanistic target of rapamycin complex 1) signaling pathway, the master regulator of cell growth, proliferation, and protein synthesis, that results from loss of the TSC1/TSC2 heterodimeric complex's GAP (GTPase-activating protein) function toward Rheb, causing Rheb-GTP accumulation that drives persistent mTORC1 activity and the subsequent uncontrolled cell growth and hamartoma formation that defines TSC's multi-organ pathology; TSC manifests across virtually every organ system through the proliferation of hamartomatous tissue derived from dysregulated mTORC1 signaling, with brain involvement (cortical tubers — focal cortical dysplasias disrupting normal six-layer cortical architecture that are the primary epileptogenic substrate, subependymal nodules lining the lateral ventricle walls, and subependymal giant cell astrocytomas (SEGAs) growing at the foramen of Monro with obstructive hydrocephalus risk), skin involvement (facial angiofibromas developing in the nasolabial fold distribution in over 75% of patients by adolescence, hypomelanotic macules or ash-leaf spots detectable under Wood's lamp ultraviolet light as the earliest and most consistent cutaneous sign, shagreen patches — connective tissue hamartomas with a peau d'orange texture over the lumbosacral region, periungual or subungual fibromas appearing in adolescence and adulthood, and forehead plaques), renal involvement (angiomyolipomas in up to 80% of TSC patients — often bilateral and multiple, with a 4 cm size threshold above which hemorrhage risk justifies mTOR inhibitor therapy or selective angioembolization, and renal cell carcinoma occurring at increased risk), pulmonary involvement (lymphangioleiomyomatosis or LAM — cystic lung destruction from smooth muscle-like cell proliferation in pulmonary interstitium occurring almost exclusively in women with TSC with a prevalence approaching 30–40% of adult TSC women, causing progressive dyspnea and pneumothorax), cardiac involvement (cardiac rhabdomyomas — the most common fetal cardiac tumor and frequently the first manifestation detected on prenatal ultrasound, typically regressing spontaneously after birth though conduction abnormalities and Wolff-Parkinson-White syndrome can persist), and ophthalmologic involvement (retinal hamartomas and astrocytic hamartomas detectable on fundoscopy in approximately 50% of TSC patients). The neurological burden of TSC dominates its clinical management: epilepsy affects 85–90% of TSC patients, is frequently severe and treatment-refractory with onset typically in infancy (infantile spasms — a catastrophic epilepsy syndrome — are the presenting seizure type in 30–40% of TSC infants and associated with worse neurocognitive outcome), and is the primary driver of intellectual disability, autism spectrum disorder (affecting approximately 50% of TSC individuals), and behavioral challenges; the EPISTOP and PREVENT trials have established that surveillance EEG detection of epileptiform activity before clinical seizure onset followed by early mTOR inhibitor (everolimus or sirolimus) therapy — taking advantage of TSC's known molecular etiology before irreversible epileptogenesis — represents a paradigm shift in TSC epilepsy management; vigabatrin remains the first-line antiseizure medication for TSC-associated infantile spasms, with mTOR inhibitor everolimus FDA-approved for TSC-associated partial-onset seizures; mTOR inhibitors (everolimus — FDA-approved for TSC-associated SEGA, renal AML, pulmonary LAM, and partial-onset seizures; sirolimus for LAM) have transformed TSC management across multiple organ systems simultaneously, reducing SEGA volume, decreasing AML size, stabilizing LAM, and reducing seizure frequency in a single systemic therapy.
TSC technology platforms — whether supporting pediatric neurology programs managing TSC-associated epilepsy with vigabatrin, everolimus, or dietary ketogenic therapy (coordinating seizure diary applications, EEG scheduling, MRI brain surveillance for cortical tuber burden and SEGA growth, antiseizure medication dose titration, and Early Infantile Epilepsy monitoring for EPISTOP-based pre-seizure EEG surveillance protocols), TSC multidisciplinary clinic platforms coordinating the multi-organ surveillance protocol recommended by the 2012 and 2021 International TSC Consensus Conference guidelines (annual renal AML MRI, brain MRI for SEGA monitoring every 1–3 years in asymptomatic patients and every 6 months in patients with growing SEGA, chest HRCT for LAM in women over 18, echocardiogram for cardiac rhabdomyomas in children, fundoscopy for retinal hamartomas, developmental neuropsychological assessment, dermatology for skin hamartoma documentation), mTOR inhibitor therapy management platforms handling everolimus prescribing and toxicity monitoring (stomatitis grading, CBC, metabolic panel, lipid panel, pulmonary toxicity surveillance, drug interaction management for CYP3A4 inhibitors and inducers with everolimus's narrow therapeutic window), neurosurgical platforms managing SEGA resection or endoscopic third ventriculostomy for obstructive hydrocephalus, interventional radiology platforms coordinating selective angioembolization for hemorrhagic or large TSC-associated renal AML, genetics platforms managing TSC1/TSC2 germline mutation sequencing and variant classification for family counseling and prenatal diagnosis, pulmonology platforms managing LAM with sirolimus and pneumothorax management, and behavioral health platforms supporting TSC-associated autism and intellectual disability care — must maintain the availability and performance standards that TSC's multi-organ complexity, epilepsy emergency risk, SEGA hydrocephalus risk, AML hemorrhage risk, and lifelong surveillance demands require. This guide explains why TSC care tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the neurological, multidisciplinary, pharmacologic, and emergency demands of modern TSC management.
Why TSC Tech Platforms Require Specialized Monitoring Attention
TSC management is defined by the life-threatening epilepsy emergency risk of TSC-associated seizure clusters and status epilepticus, the neurosurgical urgency of growing SEGA causing obstructive hydrocephalus, the interventional radiology emergency of AML hemorrhage causing Wunderlich syndrome, the pharmacologic complexity of everolimus therapy across multiple TSC manifestations simultaneously, the longitudinal neurodevelopmental surveillance obligations for a condition causing intellectual disability and autism in childhood, and the multi-organ surveillance protocol that coordinates neurology, nephrology, pulmonology, cardiology, ophthalmology, dermatology, genetics, and behavioral health across a patient's lifetime. Technology failures in these domains create disruptions calibrated to the epileptic, hydrocephalic, hemorrhagic, and surveillance consequences of TSC's systemic complexity.
Emergency epilepsy management platforms have critical impact during TSC-associated status epilepticus. Infantile spasms, focal-to-bilateral tonic-clonic seizures, and status epilepticus in TSC infants and children — where emergency EEG monitoring, antiseizure medication administration records, seizure diary synchronization, and neurology on-call communication systems are simultaneously required — depend on platforms that must be available within seconds of a seizure emergency. Monitor emergency epilepsy platforms at 1-minute intervals, 24/7.
SEGA neurosurgical management platforms have critical impact during hydrocephalic emergency. Subependymal giant cell astrocytomas growing at the foramen of Monro — where urgent brain MRI for SEGA size and hydrocephalus assessment determines whether emergency endoscopic third ventriculostomy or SEGA resection is required before irreversible neurological deterioration — require platform availability at any hour for a condition that can progress from asymptomatic to hydrocephalic emergency within weeks. Monitor SEGA neurosurgical platforms at 1-minute intervals, 24/7.
mTOR inhibitor therapy platforms determine multi-organ TSC treatment. Everolimus prescribing, toxicity monitoring, dose escalation, and pharmacy dispensing platforms — where a single mTOR inhibitor manages SEGA, renal AML, LAM, and seizures simultaneously in a patient whose multi-organ TSC burden makes therapy interruption immediately consequential across multiple organ systems — require uninterrupted availability during all clinical encounters. Monitor mTOR therapy platforms at 1-minute intervals during clinical hours.
TSC multidisciplinary surveillance platforms coordinate lifelong multi-organ monitoring. Annual renal AML MRI, brain MRI for SEGA, chest HRCT for LAM, echocardiogram for cardiac involvement, fundoscopy, neuropsychological testing, dermatology, and genetics — all coordinated through a TSC multidisciplinary clinic platform that must integrate results across specialties simultaneously — require reliable availability at every clinic cycle. Monitor TSC surveillance platforms at 1-minute intervals during clinic hours.
Early epilepsy surveillance platforms implement the EPISTOP pre-seizure monitoring protocol. EEG surveillance in TSC infants before clinical seizure onset — where routine EEG every 1–3 months in the first two years of life detects subclinical epileptiform discharges triggering immediate vigabatrin initiation before catastrophic infantile spasms develop — requires platforms managing EEG scheduling, result routing, and neurology response workflows with the urgency of a pre-epileptic emergency. Monitor EEG surveillance platforms at 1-minute intervals during clinical hours.
What to Monitor on a TSC Tech Platform
Emergency Epilepsy Management
Monitor emergency EEG acquisition, interpretation, and result routing records, antiseizure medication administration records including vigabatrin, everolimus, and benzodiazepine rescue medication documentation, seizure diary application synchronization with clinical records, status epilepticus protocol activation and emergency neurology consultation platforms, inpatient video-EEG monitoring records, and pediatric neurology on-call communication systems at 1-minute intervals, 24/7. Alert immediately — epilepsy emergency platform failures during TSC-associated status epilepticus or infantile spasm clusters eliminate neurological team access to seizure history, prior EEG interpretation, antiseizure medication dose records, and emergency protocol documentation at the moment when treatment escalation decisions determine neurological outcome.
SEGA Surveillance and Neurosurgical Management
Monitor brain MRI scheduling and SEGA volumetric measurement records, SEGA growth rate calculation documentation (comparison with prior MRI volumes at each 6-month surveillance interval for patients with known SEGA), obstructive hydrocephalus assessment records, neurosurgical consultation and operative documentation platforms, endoscopic third ventriculostomy records, SEGA resection operative documentation, postoperative neurological monitoring, and everolimus-based SEGA treatment response assessment at 1-minute intervals during clinical and operative sessions. Alert immediately — SEGA platform failures eliminate access to prior brain MRI volumetric measurements at the moment when a new MRI showing rapid SEGA growth requires immediate neurosurgical consultation and hydrocephalus management decision.
Renal AML Surveillance and Intervention
Monitor annual renal AML MRI scheduling, AML volumetric measurement records, growth rate calculation and hemorrhage risk stratification (aneurysmal vasculature identification), selective angioembolization procedure records for hemorrhagic or large AML, nephron-sparing surgery planning records, mTOR inhibitor AML response assessment MRI, creatinine and GFR monitoring for renal function preservation, and emergency angioembolization CT angiography and DSA platforms at 1-minute intervals, 24/7 for emergency platforms and during clinic hours for surveillance platforms. Alert immediately for emergency hemorrhage platforms — Wunderlich syndrome from ruptured TSC-associated renal AML presenting with retroperitoneal hematoma and hemodynamic instability requires immediate emergency angioembolization where prior renal imaging access is critical to selective feeding vessel identification.
LAM Monitoring for Female TSC Patients
Monitor chest HRCT scheduling and pulmonary cyst burden assessment records for female TSC patients over 18, pulmonary function testing records including DLCO and spirometry for LAM severity staging, sirolimus prescribing and toxicity monitoring for LAM treatment, pneumothorax management records and emergency pulmonology consultation, lung transplantation evaluation records for advanced LAM, and VEGF-D serum level monitoring (a biomarker for LAM diagnosis and treatment response) during clinical hours. Alert on sustained failures — LAM surveillance platform failures interrupt the CT and pulmonary function monitoring that detects LAM progression requiring sirolimus initiation or dose adjustment in TSC women where delayed LAM treatment accelerates cystic lung destruction.
Cardiac Rhabdomyoma and Pediatric Cardiac Monitoring
Monitor prenatal echocardiogram records for fetal cardiac rhabdomyoma detection (coordinated with obstetrics for TSC families with known germline mutation), postnatal echocardiogram records for rhabdomyoma regression surveillance, cardiac rhythm monitoring records for Wolff-Parkinson-White syndrome and other conduction abnormalities in TSC children, cardiology consultation records, and cardiac MRI for complex cardiac TSC involvement during clinical hours. Alert on sustained failures — missed cardiac rhabdomyoma regression monitoring or undetected conduction abnormalities in TSC children can result in unrecognized arrhythmia risk in a population whose cardiac involvement is already managed through an established surveillance schedule.
mTOR Inhibitor Therapy Management
Monitor everolimus and sirolimus prescribing platforms, pharmacy dispensing and refill records, stomatitis grading and supportive care documentation, CBC monitoring records for cytopenias, metabolic panel monitoring for hyperglycemia and hyperlipidemia, pulmonary toxicity surveillance records, drug level monitoring for sirolimus, drug interaction screening for CYP3A4 modulators (with everolimus requiring vigilance for concomitant azole antifungals, macrolide antibiotics, and enzyme-inducing antiseizure medications that reduce everolimus levels), dose modification records, treatment response assessment MRI for SEGA and AML, and pediatric weight-based dosing adjustment calculations during clinical hours. Alert immediately — mTOR inhibitor therapy platform failures interrupt medication management for patients whose TSC manifestations across multiple organ systems are simultaneously dependent on uninterrupted everolimus or sirolimus therapy.
Neurodevelopmental and Behavioral Surveillance
Monitor neuropsychological assessment scheduling and report integration records, autism spectrum disorder evaluation and behavioral intervention records, intellectual disability support service coordination, school accommodation planning documentation, developmental pediatrics consultation records, behavioral health platform access for TSC-associated attention deficit, anxiety, and psychiatric comorbidities, and patient and family support portal availability during clinical hours. Alert on sustained failures — neurodevelopmental surveillance platform failures delay the assessment and service coordination that determines whether TSC children with intellectual disability and autism receive timely educational and behavioral interventions.
Early EEG Surveillance (EPISTOP Protocol)
Monitor routine surveillance EEG scheduling and result routing platforms for TSC infants in the first two years of life, EEG interpretation result notification to neurology and primary TSC care team, vigabatrin initiation workflow triggered by subclinical epileptiform activity detection, and caregiver seizure diary application synchronization with clinical EEG surveillance records during clinical hours. Alert immediately — EEG surveillance platform failures delay the subclinical epileptiform activity detection that triggers early vigabatrin initiation in TSC infants before catastrophic infantile spasms develop, eliminating the clinical benefit of EPISTOP-based early intervention.
Dermatology and Skin Hamartoma Management
Monitor dermatology clinic scheduling and facial angiofibroma documentation records, laser therapy and topical rapamycin treatment records for facial angiofibromas, shagreen patch and periungual fibroma documentation, Wood's lamp hypomelanotic macule records, and dermatologic photography for longitudinal skin hamartoma comparison during clinical hours. Alert on sustained failures — dermatology documentation failures interrupt the photographic comparison records that track angiofibroma treatment response and detect new skin hamartomas at routine surveillance intervals.
Genetics and Family Counseling
Monitor TSC1 and TSC2 germline mutation sequencing and variant classification records, family cascade screening coordination for at-risk relatives, prenatal genetic counseling documentation for TSC families, preimplantation genetic testing referral records, genetic counseling session documentation, and interdisciplinary genetics conference records during clinical hours. Alert immediately — genetics platform failures during TSC1/TSC2 mutation testing result communication or family cascade screening coordination interrupt the genetic risk communication and family surveillance initiation workflow with implications for multiple family members.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. TSC programs coordinate across pediatric neurology, neurosurgery, nephrology, pulmonology, cardiology, ophthalmology, dermatology, genetics, developmental pediatrics, and behavioral health, with emergency EEG, SEGA neurosurgical, and AML hemorrhage platform access required at any hour. Authentication failures simultaneously block every multidisciplinary team member managing a patient whose neurological emergencies, SEGA hydrocephalus risk, and multi-organ surveillance all require continuous, coordinated platform access.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, seizure diary applications, EEG surveillance platforms, TSC multidisciplinary clinic systems, mTOR inhibitor pharmacy platforms, genetics portals, and LAM surveillance imaging systems. Certificate errors disrupt the emergency epilepsy, SEGA surveillance, and mTOR therapy management workflows across TSC care.
HIPAA and Neurodevelopmental Data Privacy Considerations
TSC technology platforms handle exceptionally sensitive PHI including TSC1/TSC2 germline mutation documentation with hereditary disease implications for siblings and offspring, pediatric neurological records spanning infantile spasms, cortical tuber burden, SEGA surveillance, neurocognitive assessment, intellectual disability, and autism spectrum disorder, mTOR inhibitor prescribing and toxicity records across multiple organ system indications, renal AML and pulmonary LAM surveillance records, cardiac rhabdomyoma and conduction abnormality records, prenatal genetic counseling documentation, and behavioral health records for psychiatric and behavioral TSC comorbidities. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components managing this PHI — with particular sensitivity for pediatric neurodevelopmental records and germline mutation documentation.
For platforms managing TSC germline mutation records alongside pediatric neurodevelopmental surveillance — where TSC1/TSC2 pathogenic variant documentation records a hereditary condition with childhood neurological, renal, pulmonary, cardiac, and dermatologic manifestations managed from infancy through adulthood, with predictive testing implications for siblings, family cascade screening obligations, and prenatal diagnosis decisions for TSC parents — privacy and availability standards must reflect the lifelong, multi-generational, and institutionally diverse nature of TSC PHI. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for TSC programs managing the intersection of pediatric neurology, neurosurgery, genetics, chronic pharmacotherapy, and multi-system surveillance PHI across a patient's lifetime.
Alerting Strategy for TSC Tech Platforms
Immediate 24/7 alerting for emergency platforms: Emergency EEG, status epilepticus management, SEGA neurosurgical consultation, and emergency AML angioembolization CT angiography platforms. These must be available at any hour — TSC-associated status epilepticus, SEGA hydrocephalus, and AML hemorrhage are emergencies that do not respect business hours.
Immediate alerting during operative sessions: SEGA resection and endoscopic third ventriculostomy operative documentation, AML nephron-sparing surgery planning, and intraoperative monitoring platforms during active neurosurgical and urological procedures.
Immediate business-hours alerting: mTOR inhibitor therapy management, TSC multidisciplinary clinic coordination, early EEG surveillance result routing, genetics consultation, and LAM pulmonology platforms. Alert the moment these fail during active clinical encounters.
Sustained-failure alert (10–15 minutes): Routine brain MRI and renal AML surveillance scheduling, LAM HRCT scheduling, neurodevelopmental assessment coordination, dermatology surveillance, cardiac rhabdomyoma monitoring, and TSC patient and family portal platforms.
30-day advance warning: SSL certificates across all TSC clinic, epilepsy, genetics, and patient portal domains.
Vigilmon's multi-region monitoring confirms TSC platform availability from geographies where specialized TSC multidisciplinary clinics concentrate — important for platforms supporting TSC patients whose SEGA, AML, LAM, epilepsy, and neurodevelopmental management require coordinated expert care not available at regional hospitals.
Status Page for TSC Care Team Communication
A real-time status page gives pediatric neurologists managing TSC-associated epilepsy and infantile spasms, neurosurgeons coordinating SEGA resection and hydrocephalus management, nephrologists monitoring bilateral renal AML, pulmonologists managing LAM in female TSC patients, geneticists issuing TSC1/TSC2 germline mutation reports, mTOR inhibitor-prescribing physicians coordinating everolimus toxicity monitoring, and developmental pediatricians conducting neurocognitive surveillance immediate platform visibility without requiring inbound IT support contact. During an mTOR inhibitor therapy platform outage when a TSC patient with growing bilateral AML requires everolimus dose escalation while the nephrology team cannot access prior renal MRI volumetric measurements or the current creatinine trend to calculate dosing adjustments safely, a status page enables immediate contingency protocol activation including alternative imaging record access and paper-based dosing workflows.
Include the status page URL in emergency epilepsy downtime procedures, SEGA neurosurgical fallback workflows, AML emergency angioembolization downtime protocols, and TSC multidisciplinary clinic contingency procedures.
Vigilmon Setup for TSC Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Emergency EEG / status epilepticus management (24/7) | 1 min | Slack + PagerDuty (24/7) | | SEGA brain MRI / neurosurgical consultation (24/7) | 1 min | Slack + PagerDuty (24/7) | | Emergency AML angioembolization / CT angiography (24/7) | 1 min | Slack + PagerDuty (24/7) | | mTOR inhibitor therapy management (everolimus / sirolimus) | 1 min | Slack + PagerDuty (business hours) | | TSC multidisciplinary clinic coordination | 1 min | Slack + PagerDuty (clinic hours) | | Early EEG surveillance result routing (EPISTOP) | 1 min | Slack + PagerDuty (business hours) | | Genetics / TSC1-TSC2 mutation testing / family cascade | 1 min | Slack + PagerDuty (business hours) | | LAM chest HRCT / pulmonary function / sirolimus | 1 min | Slack + PagerDuty (clinic hours) | | Renal AML surveillance MRI scheduling | 2 min | Slack (business hours) | | Routine brain MRI for cortical tuber / SEGA surveillance | 2 min | Slack (business hours) | | Neurodevelopmental / neuropsychological assessment | 2 min | Slack (business hours) | | Cardiac rhabdomyoma echocardiogram surveillance | 2 min | Slack (business hours) | | Dermatology / skin hamartoma documentation | 2 min | Slack (business hours) | | Patient and family communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure emergency EEG and status epilepticus management platforms with 24/7 immediate alerting
- Add SEGA brain MRI surveillance and neurosurgical consultation platforms with 24/7 immediate alerting
- Configure emergency AML angioembolization CT angiography and DSA platforms with 24/7 immediate alerting
- Add mTOR inhibitor therapy management and toxicity monitoring with immediate business-hours alerting
- Configure TSC multidisciplinary clinic coordination with immediate clinic-hours alerting
- Add early EEG surveillance result routing platforms with immediate business-hours alerting
- Configure genetics and TSC1/TSC2 mutation testing platforms with immediate business-hours alerting
- Add LAM chest HRCT, pulmonary function, and sirolimus management with immediate clinic-hours alerting
- Configure routine renal AML and brain MRI surveillance scheduling with sustained-failure alerting
- Add neurodevelopmental assessment, cardiac rhabdomyoma monitoring, and dermatology surveillance with sustained-failure alerting
- Enable SSL certificate monitoring across all epilepsy, TSC clinic, genetics, patient portal, and pharmacy domains
- Add the status page URL to emergency epilepsy downtime procedures, SEGA neurosurgical fallback workflows, and TSC multidisciplinary clinic contingency protocols
Conclusion
TSC technology platforms are embedded in clinical decisions where emergency epilepsy platform availability during TSC-associated infantile spasm onset in a 6-month-old infant with TSC2 germline mutation — where the pediatric neurologist requiring urgent EEG scheduling and vigabatrin initiation, the developmental pediatrician tracking neurocognitive trajectories that early seizure control preserves, and the TSC clinic coordinator updating the multi-organ surveillance calendar must simultaneously access a platform managing EEG scheduling, antiseizure medication records, early intervention referral documentation, and the EPISTOP surveillance protocol records that triggered the pre-seizure EEG — cannot be interrupted by platform outage at the precise moment when early vigabatrin initiation before clinical infantile spasm onset represents the only intervention window that prevents the catastrophic epileptic encephalopathy and irreversible neurocognitive injury that transforms a TSC infant from a child with manageable neurodevelopmental challenges into one with severe intellectual disability and autism; where SEGA neurosurgical platform availability during urgent evaluation of a 12-year-old TSC boy presenting with morning headaches and papilledema — where the neurosurgeon requiring access to the current and all prior brain MRI volumetric measurements for SEGA growth rate calculation, the neurologist reviewing the obstructive hydrocephalus grade on the new MRI, the everolimus-prescribing team determining whether SEGA has grown despite adequate mTOR inhibitor blood levels, and the neurosurgical operative planning team needing SEGA anatomical records to plan endoscopic third ventriculostomy versus SEGA resection approach — cannot be delayed by platform unavailability when the clinical difference between early surgical intervention before further hydrocephalic neurological deterioration versus delayed surgery after irreversible cerebrospinal fluid pathway injury determines the surgical risk-benefit calculation for a patient whose SEGA has grown from 12 mm to 19 mm over six months; and where annual TSC surveillance platform availability during the multidisciplinary clinic visit of a 28-year-old woman with TSC1 germline mutation — where the nephrology team reviewing bilateral AML MRI volumes for everolimus dose adequacy, the pulmonology team assessing LAM progression on chest HRCT and DLCO measurements to determine whether sirolimus should be added for LAM alongside everolimus for AML, the neurology team reviewing seizure diary data and EEG for ongoing focal epilepsy management, the genetics team updating family cascade screening status for her newly pregnant sister, and the developmental psychology team reviewing employment and independent living support requirements must all simultaneously access and coordinate through the same TSC platform — determines whether this adult patient's multi-system TSC management achieves the coordinated pharmacologic and surveillance optimization that minimizes her lifetime risk of AML hemorrhage, LAM respiratory failure, SEGA hydrocephalus, epilepsy morbidity, and the neurodevelopmental consequences that lifelong TSC inflicts across the full arc of a patient's life. A status epilepticus management platform that fails when a pediatric neurologist is escalating benzodiazepine rescue medication for a TSC toddler in refractory seizure, an mTOR inhibitor pharmacy platform inaccessible when a nephrologist must approve everolimus dispensing for a patient whose AML just exceeded bilateral intervention threshold, a TSC multidisciplinary surveillance platform unavailable when a tumor board must simultaneously review renal MRI, brain MRI, chest HRCT, and pulmonary function data to coordinate mTOR inhibitor dosing across three simultaneously active organ system indications — these are not IT incidents. They are clinical disruptions in the management of a condition whose epilepsy emergency requires 24/7 platform readiness and whose mTOR pathway-driven multi-organ complexity requires integrated surveillance platform availability across neurology, neurosurgery, nephrology, pulmonology, genetics, developmental pediatrics, and interventional radiology.
Uptime monitoring gives TSC tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to TSC multidisciplinary clinics, pediatric epilepsy programs, interventional radiology departments, genetics services, and compliance auditors that platform operational reliability matches the epilepsy emergency, SEGA hydrocephalus, AML hemorrhage, LAM respiratory, genetic, and lifelong neurodevelopmental surveillance demands of modern TSC care.
Start monitoring your TSC care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #TSC #tuberoussclerosisscomplex #TSC1 #TSC2 #mTOR #everolimus #sirolimus #epilepsy #infantilespasms #SEGA #AML #LAM #neurodevelopmental #autism #intellectualdisability #hamartoma #genetics #HIPAA #healthtech #digitalhealth #uptime #sre